Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals.
We have developed an HIV-1 reference panel of 20 subtype B envelope clones isolated from the plasma of recently infected individuals. It is widely accepted that a prophylactic vaccine against HIV-1 requires the development of novel immunogens that are capable of eliciting broadly protective neutralizing antibody responses. Historically, patient serum has been screened for such antibodies by assaying against laboratory strains, but these viruses typically have increased neutralization sensitivity compared with primary isolates. To create a more standardized and relevant assay system for vaccine evaluation, we have developed a panel of primary envelopes derived from the plasma of individuals with documented acute/early subtype B HIV-1 infection occurring between 2000 and 2004. The HIV-1 envelopes from this panel vary in mode of transmission, coreceptor tropism, fusogenicity, and overall sensitivity to neutralization. These envelope sequences represent a broad spectrum of subtype B genetic diversity with an average pairwise genetic distance of 12% and a range from 10% to 19%. This well-characterized HIV-1 envelope panel should be a valuable resource for optimizing and standardizing vaccine assessment and improving vaccine design.
Schweighardt
Becky
B
Monogram Biosciences, Inc., South San Francisco, CA, USA. bschweighardt@monogrambio.com
Liu
Yang
Y
Huang
Wei
W
Chappey
Colombe
C
Lie
Yolanda S
YS
Petropoulos
Christos J
CJ
Wrin
Terri
T
D015686:Gene Products, env / Q000235:genetics*; D014644:Genetic Variation; D015658:HIV Infections / Q000097:blood* / Q000821:virology*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009500:Neutralization Tests; D010802:Phylogeny
D015686:Gene Products, env